XO SCORE® AND XO CROSS®
ARE FDA AND CE MARK CLEARED
TARGET TREATMENT & APPLICATIONS
PERIPHERAL ARTERY DISEASE (PAD)
Increasingly complex interventions and advanced PAD disease states in require novel technologies and tools to improve the quality of care for patients. The XO Score and XO Cross platforms have been designed and optimized for dilatation and access of tough calcified lesions in the peripheral vasculature.
END-STAGE RENAL DISEASE (ESRD)
A high rate of arteriovenous fistulas and grafts fail due to excessive intimal hyperplasia-related stenoses. Dialysis interventions often require extreme high-pressure angioplasty to salvage access sites and restore flow. XO Score was designed to effectively dilatate tough, fibrous lesions encountered during fistula and graft maintenance.
The XO Score® Sheath Platform is FDA 510(k) and CE Mark cleared to be used in conjunction with a PTA balloon to facilitate dilation and apposition of the scoring surface to the stenotic material in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries; and for treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. Not for use in the coronary or neuro-vasculature. The XO Cross® Catheter Platform is also FDA 510(k) and CE Mark cleared to be used to guide and support a guidewire during access of the peripheral vasculature, allow for wire exchanges and provide a conduit for the delivery of saline solutions or diagnostic contrast agents.